RxDoctor Payments Data

Gwendolyn Henson, MD

General Practice · Clearwater, FLNPI 1700128832

Payments from drug & device makers

$3,652in general payments, 2019–2025

Across 68 payments — averaging $53.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$881
  • AstraZeneca$710
  • Amgen$294
  • Johnson & Johnson$282
  • Bayer$280
  • Lilly USA, LLC$276
  • plus $928 from 16 others

What the payments were for

  • Food & beverage$3,638100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,652 in reported general payments places this provider in the 90th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida

Medicare billing

Part B allowed, 2024
$4,782
Medicare patients
16
Services billed
71

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide66$60,860
FarxigaDapagliflozin Propanediol45$56,435
OzempicSemaglutide52$53,837
EliquisApixaban51$50,591
Tresiba Flextouch U-200Insulin Degludec14$39,958
JardianceEmpagliflozin25$36,978
MounjaroTirzepatide30$32,617
LinzessLinaclotide25$25,432
ProliaDenosumab14$24,093
CaplytaLumateperone Tosylate12$18,808
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$17,185
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog16$10,570
TradjentaLinagliptin14$10,105
Fluticasone-SalmeterolFluticasone Propion/Salmeterol44$7,767
Lantus SolostarInsulin Glargine,hum.Rec.Anlog35$5,944

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$276$93,47696 claims
AstraZenecaFarxiga, Symbicort$710$60,19658 claims
Novo NordiskOzempic$212$53,83752 claims
PfizerEliquis$17$50,59151 claims
Boehringer IngelheimJardiance, Tradjenta$53$47,08439 claims
AbbVieLinzess$881$25,43225 claims
AmgenProlia$294$24,09314 claims
GSKTrelegy Ellipta$127$17,18517 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$20$2,000181 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,901 general practice providers in Florida.

Other general practice in Clearwater

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →